MIM
RPRX icon

Monashee Investment Management’s Royalty Pharma RPRX Stock Holding History

Monashee Investment Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-120,000
Closed -$6.01M – 425
2020
Q4 		$6.01M Buy
+120,000
New +$5.09M 0.79% 21
2020
Q3 		– Sell
-180,000
Closed -$8.74M – 243
2020
Q2 		$8.74M Buy
+180,000
New +$8.91M 1.31% 12

Other funds holding RPRX

RWJF
Robert Wood Johnson Foundation Princeton, New Jersey $81M AUM 0.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Monashee Investment Management's RPRX Position: Q1 2021 in Review

Monashee Investment Management sold out of Royalty Pharma (RPRX) in Q1 2021, closing a stake of 120,000 shares — an estimated $6.01M sold.

Monashee Investment Management first reported a position in RPRX in Q2 2020 and held it in 2 quarters. The position peaked at $8.74M in Q2 2020. 214 funds tracked by Wall St. Rank hold RPRX as of Q1 2021.

  • Monashee Investment Management reported no remaining Royalty Pharma position as of Q1 2021 after selling out during the quarter.
  • Monashee Investment Management sold 120,000 Royalty Pharma shares in Q1 2021, an estimated $6.01M.
  • Monashee Investment Management first reported a position in Royalty Pharma in Q2 2020 and held it in 2 quarters.
  • Monashee Investment Management's Royalty Pharma position peaked at $8.74M in Q2 2020.
  • 214 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2021.

Based on Monashee Investment Management's 13F filing for Q1 2021, filed 14 May 2021.